For example, the TNF Receptor-One Silencer (TROS), a trivalent nanobody developed by linking two anti-human tumor necrosis factor receptor (TNFR)-1 nanobodies with an anti-albumin arm (Nb Alb-70-96), has been investigated for the selective inhibition of this pro-inflammatory pathway in autoimmune disease of the CNS in preclinical settings in rodents [68]. This evidence concerns the gene ALB and autoimmune disease.